Imidazopyridine: Difference between revisions
Content deleted Content added
m Stub sorting and placement of stub template(s) |
No edit summary |
||
| Line 13: | Line 13: | ||
[[Category:Imidazopyridines]] |
[[Category:Imidazopyridines]] |
||
Lung Cancer and T790M |
|||
The T790M mutation is a source of resistance to a previously effective drug called Tarceva. One possible use of these new type of drug is to suppress T790M. "CUDC-305 is a heat shock protein 90 (HSP90) inhibitor of the novel imidazopyridine class. Here, we report its activities in non–small cell lung cancer (NSCLC) cell lines with gene deregulations conferring primary or secondary resistance to epidermal growth factor receptor (EGFR) inhibitors. (1) |
|||
References |
|||
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer, Mol Cancer Ther December 2009 8;December 2009. |
|||
{{sedative-stub}} |
{{sedative-stub}} |
||
Revision as of 23:58, 3 September 2010
 |
The imidazopyridines are a class of sedative drugs related (in terms of their effect) to benzodiazepines. They include:
As they are not chemically related to the benzodiazepines despite their similar effect, such drugs—as well as the pyrazolopyrimidines and cyclopyrrones—are sometimes grouped together and referred to as "nonbenzodiazepines".
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |